Skeletal-Related Events in Patients With Multiple Myeloma: A Comprehensive Retrospective Cohort Study

被引:1
|
作者
Lee, Ji Yun [1 ]
Lee, Ju-Hyun [1 ]
Seo, Jeongmin [1 ]
Kang, Minsu [1 ]
Jung, Eun Hee [1 ]
Kim, Sang-A [1 ]
Suh, Koung Jin [1 ]
Kim, Ji-Won [1 ]
Kim, Se Hyun [1 ]
Lee, Jeong-Ok [1 ]
Kim, Jin Won [1 ]
Kim, Yu Jung [1 ]
Lee, Keun-Wook [1 ]
Kim, Jee Hyun [1 ]
Lee, Jong Seok [1 ]
Bang, Soo-Mee [1 ]
机构
[1] Seoul Natl Univ, Seoul Natl Univ Bundang Hosp, Coll Med, Dept Internal Med, Gumi Ro 173 Beon Gil, Seongnam 13620, South Korea
关键词
Multiple Myeloma; Skeletal-Related Events; Korean; Incidence; Risk Factors; BONE; HEALTH; COMPLICATIONS; SURVIVAL; DISEASE;
D O I
10.3346/jkms.2024.39.e175
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Multiple myeloma (MM) patients are at risk of skeletal-related events (SREs) like spinal cord compression, pathologic fractures, bone surgery, and radiation to bone. Realworld data regarding SREs in MM are limited. Methods: We conducted a large, retrospective, nationwide cohort study using the Korean Health Insurance Review and Assessment Service (HIRA) database from 2007 to 2018. Results: Over a 12-year study period, we identified 6,717 patients who developed symptomatic MM. After a median follow-up of 35.1 months (interquartile range [IQR], 20.8-58.2 months), 43.6% of these patients experienced SREs, and 39.6% had four or more SREs. One in five patients (20.0%) experienced pathologic fractures within the first year of follow-up. The median time to first SRE was 9.6 months (IQR, 1.2-25.8 months), with 3.0 months in the group with prior SREs and 19.8 months in the group without prior SREs. During follow-up, 78.5% of patients received bisphosphonates. Multiple logistic regression analysis revealed several factors associated with an increased risk of SREs, including being female (odds ratio [OR], 1.44), aged 50 or older (OR, 1.87), having cerebrovascular disease (OR, 1.34), undergoing first-line chemotherapy regimens not containing bortezomib or lenalidomide (OR, 1.49), and being in the group with prior SREs and bisphosphonate use (OR, 5.63), compared to the group without prior SREs and without bisphosphonate use. Conclusion: This population-based study is the first to report the incidence and risk factors of SREs in Korean MM patients, which can be used to assess their bone health.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [1] The cost of treating skeletal-related events in patients with multiple myeloma
    Oglesby, A.
    Barber, B.
    Lage, M. J.
    Harrison, D. J.
    Jun, S.
    VALUE IN HEALTH, 2008, 11 (03) : A69 - A69
  • [2] Predictors for skeletal-related events in patients with advanced multiple myeloma
    Terpos, Evangelos
    Cook, Richard
    Coleman, Robert
    Lipton, Allan
    Berenson, James
    BLOOD, 2007, 110 (11) : 443A - 444A
  • [3] Incidence of Skeletal-Related Events Among Multiple Myeloma Patients: A Nationwide Population-Based Cohort Study
    Lee, Ji Yun
    Lee, Ju Hyun
    Kim, Sang-A
    Suh, Koung Jin
    Kim, Ji-Won
    Kim, Se Hyun
    Lee, Jeong-Ok
    Kim, Jin Won
    Kim, Yu Jung
    Lee, Keun-Wook
    Kim, Jee Hyun
    Lee, Jong-Seok
    Bang, Soo-Mee
    Jung, Eun Hee
    Kang, Minsu
    BLOOD, 2022, 140 : 12570 - 12570
  • [4] HEALTHCARE RESOURCE UTILIZATION AND COSTS OF SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA
    Bhowmik, D.
    Hines, D. M.
    Intorcia, M.
    McGuiness, C. B.
    Wade, R. L.
    VALUE IN HEALTH, 2017, 20 (05) : A103 - A103
  • [5] Impact of skeletal-related events on multiple myeloma treatment.
    Bhowmik, Debajyoti
    Shi, Nianwen
    Manjelievskaia, Janna
    Song, Xue
    Vidito, Sarah
    Intorcia, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Economic evaluation of denosumab in the prevention of skeletal-related events in patients with multiple myeloma in Mexico
    Carlos-Rivera, Fernando
    Guzman-Caniupan, Jorge A.
    Hernandez-Garduno, Adolfo
    Alva-Esqueda, Monica
    Aubry-de Maraumont, Therese
    Camacho-Cordero, Luis M.
    GACETA MEXICANA DE ONCOLOGIA, 2022, 21 (02): : 59 - 69
  • [7] BUDGET IMPACT OF DENOSUMAB IN THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA IN COLOMBIA
    Perez, M.
    Jamotte, A.
    Amaya, J.
    Linares, F.
    VALUE IN HEALTH, 2018, 21 : S290 - S290
  • [8] Zoledronic acid and skeletal-related events in patients with bone metastatic cancer or multiple myeloma
    Jeon, Ha-Lim
    Oh, In-Sun
    Baek, Yeon-Hee
    Yang, Hyowon
    Park, Jeehye
    Hong, Soojung
    Shin, Ju-Young
    JOURNAL OF BONE AND MINERAL METABOLISM, 2020, 38 (02) : 254 - 263
  • [9] Retrospective Database Analysis of the Effect of Zoledronic Acid (ZOL) On Skeletal-Related Events (SREs) in Patients (Patients) with Multiple Myeloma (MM)
    Henk, Henry J.
    Kaura, Satyin
    Perez, Jose Ricardo
    Becker, Laura
    BLOOD, 2009, 114 (22) : 1493 - 1493
  • [10] Zoledronic acid and skeletal-related events in patients with bone metastatic cancer or multiple myeloma
    Ha-Lim Jeon
    In-Sun Oh
    Yeon-Hee Baek
    Hyowon Yang
    Jeehye Park
    Soojung Hong
    Ju-Young Shin
    Journal of Bone and Mineral Metabolism, 2020, 38 : 254 - 263